Home > Boards > US Listed > Medical - Drugs > Oramed Pharmaceuticals (ORMP)


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Fmello Member Profile
Followed By 4
Posts 695
Boards Moderated 0
Alias Born 04/15/19
160x600 placeholder
Oramed subsidiary to start clinical trials for its oral COVID-19 vaccine candidate Seeking Alpha - 7/21/2021 9:28:25 AM
Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial PR Newswire (US) - 7/21/2021 8:25:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 7/16/2021 4:16:12 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 7/15/2021 5:07:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/15/2021 4:16:49 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/14/2021 4:32:06 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/8/2021 4:30:49 PM
Oramed Pharmaceuticals to join Russell 2000 and 3000 Index Seeking Alpha - 6/22/2021 8:50:19 AM
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes PR Newswire (US) - 6/22/2021 8:40:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/16/2021 4:09:44 PM
Registration of Additional Securities (up to 20%) (s-3mef) Edgar (US Regulatory) - 6/16/2021 9:37:50 AM
Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study PR Newswire (US) - 6/8/2021 8:10:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/25/2021 4:06:12 PM
Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine PR Newswire (US) - 5/25/2021 8:40:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2021 4:16:04 PM
Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners' Grand Rounds: A Webinar in Biotech and ... PR Newswire (US) - 4/21/2021 7:25:00 AM
Oramed Pharma initiated buy at Cantor citing the potential of oral insulin therapy Seeking Alpha - 4/20/2021 3:59:21 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/13/2021 4:20:14 PM
Oramed initiates second phase 3 study of oral insulin candidate; shares up 14% Seeking Alpha - 3/23/2021 9:39:49 AM
Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol PR Newswire (US) - 3/23/2021 8:51:00 AM
ORMP, MOGO, LIZI and LEAF among premarket gainers Seeking Alpha - 3/23/2021 8:23:50 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/23/2021 7:37:27 AM
Premas Biotech et Oramed annoncent un vaccin candidat oral contre la COVID-19 qui produit des anticorps après une seule dose Business Wire - 3/22/2021 3:06:00 AM
Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose Business Wire - 3/19/2021 10:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/19/2021 9:07:51 AM
Fmello   Tuesday, 04/13/21 05:33:50 PM
Re: None
Post # of 940 

Phase III Trial: Based on guidance received from the FDA as part of the End-of-Phase 2 meeting process for our oral insulin candidate, ORMD-0801, we have submitted to the FDA the protocols for our upcoming pivotal Phase III studies. In line with the FDA's expectations and recommendations, we intend to conduct two Phase 3 studies concurrently in patients with type 2 diabetes, or T2D. These studies involve about 1,125 patients to provide evidence of ORMD-0801's safety and efficacy in T2D patients over a treatment period of 6 to 12 months. A geographically diverse patient population will be recruited from multiple sites throughout the U.S., European Union countries, and Israel. Our phase III trial will be composed of 2 protocols:

ORA-D-013-1: This trial will treat T2D patients with inadequate glycemic control who are currently on 1, 2, or 3 oral glucose-lowering agents. This U.S. trial will recruit 675 patients from 75 clinical sites located throughout the U.S. Patients will be randomized 1:1:1 in this double-dummy trial into cohorts of: 8 mg ORMD-0801 once-daily at night and placebo 45 minutes before breakfast; 8 mg ORMD-0801 twice-daily, at night and 45 minutes before breakfast; and placebo twice-daily, at night and 45 minutes before breakfast. The primary endpoint of the trial is to evaluate the efficacy of ORMD-0801 compared to placebo in improving glycemic control as assessed by HbA1c, with a secondary efficacy endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks. We initiated this trial in the fourth quarter of 2020. In March 2021, we announced that 25% of the 675 patients were enrolled and randomized.

ORA-D-013-2: This trial will include T2D patients with inadequate glycemic control who are manage their condition with either diet alone or with diet and metformin monotherapy. A total of 450 patients will be recruited through 36 sites in the U.S. and 25 sites in Western Europe and Israel. Patients will be randomized 1:1 into two cohorts dosed with 8 mg ORMD-0801 at night; and placebo at night. The primary endpoint is to evaluate the efficacy of ORMD-0801 compared to placebo in improving glycemic control as assessed by HbA1c over a 26-week treatment period, with a secondary efficacy endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks. We initiated this trial in the U.S. in the first calendar quarter of 2021.

We expect to receive the efficacy data from the trials after patients have completed the first 6-months of treatment. Safety will be further monitored as patients will be exposed to the drug over an additional 6 months (total 12 months). The trial's topline results are expected in 2022 and we anticipate filing a BLA with the FDA in 2023. A BLA would grant us 12 years of marketing exclusivity from the date of approval in the U.S.

NASH trial: In June 2020, we presented topline data from an open-label trial of 8 patients that assessed the safety, tolerability, and early effects of 16 mg ORMD-0801 (2x8 mg capsules) on liver fat in T2D patients with nonalcoholic steatohepatitis, or NASH. The 12-week dosing had no serious adverse events and it induced an observed mean 6.9?6.8% reduction in liver fat content (p-value:

In December 2020, based on the NASH trial results, we initiated a follow-on clinical trial of our oral insulin capsule ORMD-0801 for the treatment of NASH. This 40 patients multi-center trial will be comprised of eight clinical sites:

Oral Glucagon-Like Peptide-1: GLP-1 is an incretin hormone, which stimulates the secretion of insulin from the pancreas. In addition to our flagship product, the ORMD-0801 insulin capsule, we use our technology for an orally ingestible GLP-1 capsule, or ORMD-0901.

In February 2019, we completed a Phase I pharmacokinetic trial to evaluate the safety and pharmacokinetics of ORMD-0901 compared to placebo. We intend on initiating a follow-on trial in T2D patients, which is expected to start during the first half of 2021 in the U.S. under an IND submitted to the FDA.

Other products
We are developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule. We anticipate initiating a proof of concept single-dose trial for this candidate to evaluate its pharmacokinetics and pharmacodynamics (glucagon reduction) in 10 type 1 adult diabetic patients. During the third quarter of 2020, we finalized the trial without any safety issues. Patients who received leptin on average had a decrease in glucose as compared to the placebo group during the first 30-180 minutes following dosing. At different time periods, the leptin treated patients on average had glucagon values that were either lower than or similar to, those in the placebo group.

Oravax License
On March 18, 2021, we entered into a License Agreement, or the Oravax License Agreement, with Oravax Medical Inc., or Oravax, pursuant to which we will grant to Oravax an exclusive, worldwide license, or the License, under our rights in certain patents and related intellectual property in which Oravax will receive certain rights relating to our proprietary oral delivery technology to further develop, manufacture and commercialize oral vaccines for COVID-19 and other novel coronaviruses based on Premas Biotech Pvt. 's, or Premas, proprietary vaccine technology involving a triple antigen virus like particle, or the Oravax Product which was previously owned by Cystron Biotech LLC, or Cystron, and later acquired by Akers Biosciences Inc., or Akers.

In consideration for the grant of the License, the Oravax License Agreement provides that we will receive (i) royalties equal to 7.5% on net sales, as defined in the Oravax License Agreement, of each product commercialized by Oravax, its affiliates and permitted sublicensees related to the License during the term specified in the Oravax License Agreement, (ii) sublicensing fees equal to 15% of any non-sales-based consideration received by Oravax from a permitted sublicensee and (iii) other payments ranging between $25 million to $100 million, based on certain sales milestones being achieved by Oravax. The parties further agreed to establish a development and steering committee, which will consist of three members, of which two members will be appointed by us, that will oversee the ongoing research, development, clinical and regulatory activity with respect to the Oravax Product. In addition, we agreed to buy and Oravax agreed to issue to us 1,890,000 shares of common stock of Oravax, representing 63% of the common stock of Oravax for the aggregate amount of $1.5 million. Akers agreed to contribute to Oravax $1.5 million in cash and substantially all of the assets of Cystron, including a license agreement to the Premas novel vaccine technology.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences